Publications
Detailed Information
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Kim, Sang-We | - |
dc.contributor.author | Camidge, D. Ross | - |
dc.contributor.author | Shu, Catherine A. | - |
dc.contributor.author | Marrone, Kristen A. | - |
dc.contributor.author | Le, Xiuning | - |
dc.contributor.author | Blakely, Collin M. | - |
dc.contributor.author | Park, Keunchil | - |
dc.contributor.author | Chang, Gee-Chen | - |
dc.contributor.author | Patel, Sandip Pravin | - |
dc.contributor.author | Kar, Gozde | - |
dc.contributor.author | Cooper, Zachary A. | - |
dc.contributor.author | Samadani, Ramin | - |
dc.contributor.author | Pluta, Michael | - |
dc.contributor.author | Kumar, Rakesh | - |
dc.contributor.author | Ramalingam, Suresh | - |
dc.date.accessioned | 2023-05-10T01:22:35Z | - |
dc.date.available | 2023-05-10T01:22:35Z | - |
dc.date.created | 2023-04-26 | - |
dc.date.created | 2023-04-26 | - |
dc.date.created | 2023-04-26 | - |
dc.date.created | 2023-04-26 | - |
dc.date.created | 2023-04-26 | - |
dc.date.created | 2023-04-26 | - |
dc.date.created | 2023-04-26 | - |
dc.date.created | 2023-04-26 | - |
dc.date.issued | 2023-05 | - |
dc.identifier.citation | Journal of Thoracic Oncology, Vol.18 No.5, pp.650-656 | - |
dc.identifier.issn | 1556-0864 | - |
dc.identifier.uri | https://hdl.handle.net/10371/192261 | - |
dc.description.abstract | Introduction: CD73 is overexpressed in EGFR-mutated NSCLC and may promote immune evasion, suggesting potential for combining CD73 blockers with EGFR tyrosine kinase inhibitors (TKIs). This phase 1b-2 study (NCT03381274) evaluated the anti-CD73 antibody oleclumab plus the third-generation EGFR TKI osimertinib in advanced EGFR-mutated NSCLC. Methods: Patients had tissue T790M-negative NSCLC with TKI-sensitive EGFR mutations after progression on a first- or second-generation EGFR TKI and were osimertinib naive. They received osimertinib 80 mg orally once daily plus oleclumab 1500 mg (dose level 1 [DL1]) or 3000 mg (DL2) intravenously every 2 weeks. Primary end points included safety and objective response rate by Response Evaluation Criteria in Solid Tumors version 1.1. Results: By July 9, 2021, five patients received DL1 and 21 received DL2. Of these patients, 60.0% and 85.7% had any-grade treatment-related adverse events (TRAEs) and 20.0% and 14.3% had grade 3 TRAEs, respectively. No dose-limiting toxicities, serious TRAEs, or deaths occurred. Four patients were T790M positive on retrospective circulating tumor DNA (ctDNA) testing; three had objective partial responses. In patients who were T790M negative in tumor and ctDNA, objective response rate was 25.0% at DL1 and 11.8% at DL2 (all partial responses); response durations at DL2 were 14.8 and 16.6 months. In patients receiving DL2, excluding those who were T790M positive by ctDNA, median progression-free survival was 7.4 months, and median overall survival was 24.8 months. DL2 was the recommended phase 2 dose. Conclusions: Oleclumab plus osimertinib was found to have moderate activity with acceptable tolerability in previously treated patients with advanced EGFR-mutated NSCLC. | - |
dc.language | 영어 | - |
dc.publisher | Elsevier Inc. | - |
dc.title | CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.jtho.2022.12.021 | - |
dc.citation.journaltitle | Journal of Thoracic Oncology | - |
dc.identifier.wosid | 000984821300001 | - |
dc.identifier.scopusid | 2-s2.0-85147560675 | - |
dc.citation.endpage | 656 | - |
dc.citation.number | 5 | - |
dc.citation.startpage | 650 | - |
dc.citation.volume | 18 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordAuthor | CD73 | - |
dc.subject.keywordAuthor | EGFR TKI resistance | - |
dc.subject.keywordAuthor | Non–small-cell lung cancer | - |
dc.subject.keywordAuthor | T790M-negative | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.